Skip to main content

Advertisement

Fig. 4 | Cancer Communications

Fig. 4

From: Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

Fig. 4

The effect of crizotinib on CTC15035EML4–ALK xenografts and their development of crizotinib resistance. a CTC15035EML4–ALK xenograft growth curves for female nu/nu mice (mean ± SEM, n = 6) treated with 50 mg/kg crizotinib or vehicle control for 21 days. b CTC15035EML4–ALK xenograft growth curves in six female nu/nu mice (crizotinib 1–6) for 114 days with 50 mg/kg crizotinib (mean ± SEM, n = 6). c Secondary CTC15035EML4–ALK xenografts derived from crizotinib-6 under 50 mg/kg crizotinib or vehicle control treatments (mean ± SEM, n = 6). d Fusion transcripts of EML4 Exon 18 to ALK Exon 20, which occurred in the tumor biopsy from patient CTC15035EML4–ALK and the CTC15035EML4–ALK xenografts, were identified by RNA amplification sequencing with an ultra-deep sequencing depth of approximately 50,000-fold of the EML4ALK fusion locus; e the novel acquired ALK E1210K mutation in crizotinib-6 xenografts at a frequency of 9% (d, e are displayed with Integrative Genomics Viewer)

Back to article page